Physician

Oncology

Dr. Richard Piekarz, MD

Richard Piekarz works in the field of Oncology. He went to medical school at Albert Einstein College of Medicine of Yeshiva University. Dr. Richard Piekarz is a published physician. He published 35 publications, including: 'Safety-modified episomal vectors for human gene therapy.'

Publications

A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent.
A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study.
Phase I trial of a new schedule of romidepsin in patients with advanced cancers.
Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocyt...
T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mecha...
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.
Safety-modified episomal vectors for human gene therapy.
Progesterone regulates the murine multidrug resistance mdr1b gene.
Three distinct nuclear protein binding sites in the promoter of the murine multidrug resistance mdr1b gene.
Structural and functional analysis of the mouse mdr1b gene promoter.
Biochemical and genetic characterization of the multidrug resistance phenotype in murine macrophage-like J774.2 cells.
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report.
Epigenetic modifiers: basic understanding and clinical development.
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
Histone deacetylase inhibitors in combinations: will the preclinical promises be kept?
Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.
Challenges of evaluating the cardiac effects of anticancer agents.
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma.
Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).
Effect of a histone deacetylase inhibitor on human cardiac mass.
Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry.
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies.
Impact of ABCB1 allelic variants on QTc interval prolongation.
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.
Religious tradition and concern for the welfare of all living beings.
Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.
A review of depsipeptide and other histone deacetylase inhibitors in clinical trials.

Schools

Albert Einstein College of Medicine of Yeshiva University
University Hosps Of Cleveland
Nih National Cancer Institute

Doctors Specialties

Medical Oncology
Oncology

Accepted Insurances

Education

National Institutes of Health Clinical Center
Case Western Reserve University - University Hospitals
Albert Einstein College of Medicine of Yeshiva University

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Michael J. Hamilton, MD
	Dr. Adrian M. Senderowicz, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Alain Thibault, MD
	Dr. Cliona M. Grant, MD This Doctor is OpenDoctor Recommended.
	Dr. Stanley Lipkowitz, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Richard A. Binder, MD This Doctor is OpenDoctor Recommended.
	Dr. Jaye L. Viner, MD This Doctor is OpenDoctor Recommended.
	Dr. Richard J. Hodes, MD This Doctor is OpenDoctor Recommended. This doctor has more publications